Your browser doesn't support javascript.
loading
Acute myeloid leukemia with an MN1-ETV6 fusion in a young child with Down syndrome.
Rosenzweig, Jaclyn; Pillai, Pallavi M; Prockop, Susan; Benayed, Ryma; Eidenschink Brodersen, Lisa; Najfeld, Vesna; Loken, Michael R; Zhang, Yanming; Shukla, Neerav.
Afiliação
  • Rosenzweig J; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Pillai PM; Department of Pediatrics, Division of Pediatric Hematology-Oncology, Mount Sinai Kravis Children's Hospital, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
  • Prockop S; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Benayed R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Eidenschink Brodersen L; Hematologics, Inc., Seattle, Washington 98121, USA.
  • Najfeld V; Department of Medicine and Pathology, Tumor Cytogenomics, Icahn School of Medicine at Mount Sinai Hospital, New York, New York 10029, USA.
  • Loken MR; Hematologics, Inc., Seattle, Washington 98121, USA.
  • Zhang Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
  • Shukla N; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Article em En | MEDLINE | ID: mdl-35483876
ABSTRACT
Myeloid leukemia of Down syndrome (ML-DS) in young children is associated with distinct clinical and biological features and is typically initiated with oncogenic mutations in the X-linked megakaryocytic transcription factor GATA1. Here we present a 3-yr-old child with DS diagnosed with acute myeloid leukemia (AML), which lacks typical immunophenotypic and molecular characteristics of ML-DS, including GATA1 mutations. The leukemic blasts were found to have an MN1-ETV6 gene fusion, a high-risk oncofusion not previously described in DS patients. This report highlights the importance of immunophenotypic, cytogenetic, and molecular characterization of ML-DS for identification of rare cases with unique features that may benefit from treatment protocols that are more intensive than those developed for patients with typical GATA1 mutant ML-DS.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Repressoras / Leucemia Mieloide Aguda / Síndrome de Down / Proteínas Proto-Oncogênicas c-ets Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Repressoras / Leucemia Mieloide Aguda / Síndrome de Down / Proteínas Proto-Oncogênicas c-ets Idioma: En Ano de publicação: 2022 Tipo de documento: Article